Archives: Speakers

At Curie.Bio, I work with portfolio companies to shape and execute clinical development strategies, helping to turn scientific ideas into medicines that matter to patients. I joined Curie.Bio because I was impressed by the unique model of working alongside founders to help new companies grow. I am excited to drive the development of emerging biotechs with nimble organizations which requires combing strategic and hands-on multidisciplinary experiences expertise. I am proud to be part of the team displaying a unique combination of company-building- and drug discovery experience.

Before joining Curie.Bio, I was VP, Strategic Consulting in Clinical Development and Innovative Quantitative Sciences at Cytel, where I advised biopharma and medtech companies on clinical development and supported VC and PE firms with due diligence to de-risk and optimize investments through adaptive clinical development strategies.

I built over 20 years of international leadership experience, holding roles of increasing responsibility and leading cross-functional, multidisciplinary teams in the life sciences industry. My background spans global strategy, hands-on business and R&D leadership, and P&L ownership, including my role as Global Category Head, Acute Care–Oncology at Nestlé Health Science. I further acted as a Jury Member for the European Commission’s new European Innovation Council (EIC), interviewing C-level leadership to provide go/no-go decisions to the European Investment Fund.

Clinical Research and Development professional with over twenty five years in Biomedical Research, Biostatistics, Statistical Programming, and Data Management. Management experience includes biostatistics, statistical programming, data management, projects and 10 direct reports. Excellent communication, leadership, and collaboration skills. Establish and develop standard procedure and guidance for Biostatistics and Statistical Programming.Broad experience includes providing statistical support for phase I-IV clinical trials, NDA submissions, integrated summary of safety (ISS) and efficacy (ISE). Therapeutic areas include diabetes, oncology, metabolic, neuroscience, pain management, transplant, hepatitis, psoriasis, cardiology, gastroenterology, inflammatory disease, rare disease, and rheumatology.

Elizabeth Drake is Founder and President of CS2 Inc., bringing nearly 40 years of experience helping industrial organizations optimize operations, safety, compliance, and reliability. She is a technology advocate focused on practical solutions that connect people, processes, and data to drive better business outcomes.

Currently leading product marketing and go-to-market strategy efforts for Private Networks at Ericsson, Matt and his team are responsible for development of use cases, positioning, and messaging, along with the evolution and execution Ericsson’s Enterprise Wireless Solutions go-to-market strategy for private networks.

Matt is focused on enabling partners and customers to capitalize on opportunities that private cellular brings to the enterprise such as automation, efficiency, and increased safety.

Ammar Sabbagh is an expert in IoT, 4/5G with a focus on the Oil & Gas and Ports industries

Sabbagh loves to explore the possibilities of new technologies. Thus, he has spent most of his career advancing innovation within large corporations- Ericsson, Time Warner Telecom and Marconi, where he launched new products, solutions and secured revenue. He has wide experience in enterprise solutions for digitalization and automation for Oil & Gas and Ports.

Sabbagh lived and studied in Portland, Oregon, USA. He has an MBA from Marylhurst University and B.S. in electrical engineering from Portland State University

​​Krystal Haynes serves as the Senior Director of International 3PL Business Development for ICS – part of the Cencora family of companies. In her role, Krystal is responsible for the strategic and operational oversight of the ICS business development team, supporting manufacturers for their commercial launch, including innovative cell and gene therapies.​

GertJan (GJ) brings 25+ years commercial experience across clinical development and commercialisation. He has broad experience across clinical development and market access with leading CROs like ICON, PAREXEL and PPD. In his current role VP Integrated Solutions & Commercialisation he leverages Cencora’s foundations to bring integrated outsourced commercial services to emerging biotechs in Europe and/or the US.